SG11201908051RA - Modified human igm constant regions for modulation of complement-dependent cytolysis effector function - Google Patents

Modified human igm constant regions for modulation of complement-dependent cytolysis effector function

Info

Publication number
SG11201908051RA
SG11201908051RA SG11201908051RA SG11201908051RA SG11201908051RA SG 11201908051R A SG11201908051R A SG 11201908051RA SG 11201908051R A SG11201908051R A SG 11201908051RA SG 11201908051R A SG11201908051R A SG 11201908051RA SG 11201908051R A SG11201908051R A SG 11201908051RA
Authority
SG
Singapore
Prior art keywords
international
complement
modulation
pct
constant regions
Prior art date
Application number
SG11201908051RA
Inventor
Ramesh Baliga
Dean Ng
Original Assignee
Igm Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igm Biosciences Inc filed Critical Igm Biosciences Inc
Publication of SG11201908051RA publication Critical patent/SG11201908051RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Abstract

N O N N co (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 October 2018 (11.10.2018) WIPO PCT omit VIII °nolo OH mo molionflou (10) International Publication Number WO 2018/187702 A2 (51) International Patent Classification: C12Q 1/68 (2018.01) (21) International Application Number: PCT/US2018/026474 (22) International Filing Date: 06 April 2018 (06.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/483,087 07 April 2017 (07.04.2017) US (71) Applicant: IGM BIOSCIENCES A/S [DK/US]; Haldor Topsoes All& 1, 2800 Kgs. Lyngby (DK). (72) Inventors: BALIGA, Ramesh; 2237 Hopkins Avenue, Redwood City, California 94062 (US). NG, Dean; 3966 18th Street, San Francisco, California 94114 (US). (74) Agent: HAANES, Elizabeth J.; FisherBroyles LLP, 945 East Paces Ferry Road N.E., Suite 2000, Atlanta, GA 30328 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with declaration under Article 17(2)(a); without abstract; title not checked by the International Searching Authority 1-1 (54) Title: MODIFIED HUMAN IGM CONSTANT REGIONS FOR MODULATION OF COMPLEMENT-DEPENDENT CY- TOLYSIS EFFECTOR FUNCTION 0 (57) :
SG11201908051RA 2017-04-07 2018-04-06 Modified human igm constant regions for modulation of complement-dependent cytolysis effector function SG11201908051RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762483087P 2017-04-07 2017-04-07
PCT/US2018/026474 WO2018187702A2 (en) 2017-04-07 2018-04-06 Modified human igm constant regions for modulation of complement-dependent cytolysis effector function

Publications (1)

Publication Number Publication Date
SG11201908051RA true SG11201908051RA (en) 2019-09-27

Family

ID=63713537

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908051RA SG11201908051RA (en) 2017-04-07 2018-04-06 Modified human igm constant regions for modulation of complement-dependent cytolysis effector function

Country Status (11)

Country Link
US (2) US11401337B2 (en)
EP (1) EP3607091A4 (en)
JP (2) JP2020512820A (en)
KR (1) KR20190137821A (en)
CN (1) CN110536900A (en)
AU (1) AU2018248336A1 (en)
CA (1) CA3055790A1 (en)
IL (1) IL268901A (en)
MX (1) MX2019011986A (en)
SG (1) SG11201908051RA (en)
WO (1) WO2018187702A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105992772A (en) 2014-02-10 2016-10-05 Igm生命科学股份有限公司 IgA multi-specific binding molecules
IL278350B (en) 2014-04-03 2022-06-01 Igm Biosciences Inc Modified j-chain
CN107207601A (en) 2015-01-20 2017-09-26 Igm生物科学股份有限公司 TNF (TNF) superfamily receptors binding molecule and its application
ES2874558T3 (en) 2015-03-04 2021-11-05 Igm Biosciences Inc CD20-binding molecules and their uses
JP6882184B2 (en) 2015-03-25 2021-06-02 アイジーエム バイオサイエンシズ インコーポレイテッド Multivalent hepatitis B virus antigen-binding molecule and its use
US10570191B2 (en) 2015-04-17 2020-02-25 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
EP3355913A1 (en) 2015-09-30 2018-08-08 IGM Biosciences A/S Binding molecules with modified j-chain
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
KR102343742B1 (en) 2016-05-09 2021-12-24 아이쥐엠 바이오사이언스 인코포레이티드 anti-PD-L1 antibody
MX2020009069A (en) 2018-03-01 2020-10-08 Igm Biosciences Inc IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE.
US20210380701A1 (en) * 2018-10-23 2021-12-09 Igm Biosciences, Inc. MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES
MX2022013334A (en) 2020-04-22 2022-12-06 Igm Biosciences Inc Pd-1 agonist multimeric binding molecules.
WO2023150677A2 (en) * 2022-02-03 2023-08-10 Igm Biosciences, Inc. Anti-cd38 binding molecules and uses thereof
WO2023196995A1 (en) 2022-04-07 2023-10-12 Repertoire Immune Medicines, Inc. T cell receptor multimers and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256771A (en) 1990-04-03 1993-10-26 Miles Inc. Heat treatment of IgM-containing immunoglobulins to eliminate non-specific complement activation
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
US20150071948A1 (en) * 2003-09-26 2015-03-12 Gregory Alan Lazar Novel immunoglobulin variants
CA2551008C (en) 2003-12-25 2013-10-01 Kirin Beer Kabushiki Kaisha Anti-cd40 antibody mutants
AU2005304973A1 (en) 2004-11-05 2006-05-18 Palingen, Inc. Antibody induced cell membrane wounding
WO2011056997A1 (en) 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
MX363819B (en) 2012-02-08 2019-04-03 Igm Biosciences Inc Cdim binding proteins and uses thereof.
JP6721505B2 (en) 2013-09-05 2020-07-15 アイジーエム バイオサイエンシズ インコーポレイテッド Constant-chain modified bispecific pentavalent and hexavalent Ig-M antibodies
US9416496B2 (en) * 2013-10-16 2016-08-16 Georgia-Pacific Consumer Products Lp Method for reducing the bulk and increasing the density of a tissue product
CN105992772A (en) 2014-02-10 2016-10-05 Igm生命科学股份有限公司 IgA multi-specific binding molecules
TW201536801A (en) 2014-02-25 2015-10-01 Fujirebio Kk Modified monomeric IgM
IL278350B (en) 2014-04-03 2022-06-01 Igm Biosciences Inc Modified j-chain
CN107207601A (en) 2015-01-20 2017-09-26 Igm生物科学股份有限公司 TNF (TNF) superfamily receptors binding molecule and its application
ES2874558T3 (en) 2015-03-04 2021-11-05 Igm Biosciences Inc CD20-binding molecules and their uses
JP6882184B2 (en) 2015-03-25 2021-06-02 アイジーエム バイオサイエンシズ インコーポレイテッド Multivalent hepatitis B virus antigen-binding molecule and its use
US10570191B2 (en) 2015-04-17 2020-02-25 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
EP3355913A1 (en) 2015-09-30 2018-08-08 IGM Biosciences A/S Binding molecules with modified j-chain
CN105441455B (en) * 2015-10-21 2020-08-28 重庆金迈博生物科技有限公司 Chimeric nucleic acid molecule and application thereof in preparation of humanized antibody
KR102343742B1 (en) 2016-05-09 2021-12-24 아이쥐엠 바이오사이언스 인코포레이티드 anti-PD-L1 antibody
EP3487299A4 (en) 2016-07-20 2020-03-11 IGM Biosciences, Inc. Multimeric gitr binding molecules and uses thereof
CA3030647A1 (en) 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric ox40 binding molecules and uses thereof
AU2017299610B2 (en) 2016-07-20 2022-09-29 Igm Biosciences, Inc. Multimeric CD40 binding molecules and uses thereof
WO2018017761A1 (en) 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric cd137/4-1bb binding molecules and uses thereof
AU2019224136A1 (en) 2018-02-26 2020-09-10 Igm Biosciences, Inc. Use of a multimeric anti-DR5 binding molecule in combination with a chemotherapeutic agent for treating cancer
MX2020009069A (en) 2018-03-01 2020-10-08 Igm Biosciences Inc IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE.
US20210380701A1 (en) 2018-10-23 2021-12-09 Igm Biosciences, Inc. MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES

Also Published As

Publication number Publication date
MX2019011986A (en) 2019-11-07
US20220340676A1 (en) 2022-10-27
EP3607091A4 (en) 2021-01-20
JP2020512820A (en) 2020-04-30
KR20190137821A (en) 2019-12-11
EP3607091A2 (en) 2020-02-12
US11401337B2 (en) 2022-08-02
US20210147567A1 (en) 2021-05-20
IL268901A (en) 2019-10-31
CN110536900A (en) 2019-12-03
JP2023085503A (en) 2023-06-20
CA3055790A1 (en) 2018-10-11
AU2018248336A1 (en) 2019-09-26
WO2018187702A2 (en) 2018-10-11

Similar Documents

Publication Publication Date Title
SG11201908051RA (en) Modified human igm constant regions for modulation of complement-dependent cytolysis effector function
SG11201809336QA (en) Anti-pd-l1 antibodies
SG11201808724SA (en) Anti-tim-3 antibodies and compositions
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201807437XA (en) Antibodies specific to human poliovirus receptor (pvr)
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201809857TA (en) Anti-CTLA-4 Antibodies
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201810034XA (en) ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
SG11201910134SA (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201906552WA (en) TGF-ß DECOY RECEPTOR
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201909009TA (en) Catheter securement device with window
SG11201908678XA (en) Methods and compositions for reduction of immunogenicity
SG11201907948TA (en) Formulations comprising pd-1 binding proteins and methods of making thereof
SG11201909466RA (en) Human anti-semaphorin 4d antibody
SG11201901597UA (en) Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
SG11201908744PA (en) Anti-c5a antibodies and uses thereof